CEP290 — centrosomal protein 290

The CEP290 gene provides essential instructions for making a protein that acts like a gatekeeper in many cells of the body, particularly in the eye. In the retina, the light-sensing cells (photoreceptors) have a specialized structure called a cilium, which acts like a bridge connecting different parts of the cell. The CEP290 protein sits at this bridge and controls the traffic of important materials back and forth. This constant transport is absolutely necessary for the photoreceptors to detect light and send visual signals to the brain. When the CEP290 gene is mutated, the gatekeeper protein is either missing or doesn't work correctly. As a result, the vital traffic across the cellular bridge gets blocked. In the eye, this causes the light-sensing cells to slowly break down and die, leading to severe vision loss. Because the CEP290 protein is also used in cilia in other parts of the body, such as the kidneys and brain, some mutations can cause additional health problems in those organs, though many patients only experience vision loss. Conditions caused by CEP290 mutations are inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene—one from each parent—to develop the disease. The parents, who each carry one mutated copy and one normal copy, typically do not show any symptoms and are known as carriers. For families with a history of CEP290-related disease, genetic testing and counseling can help determine the risk of passing the condition to future children.

Gene description: CEP290 encodes a large centrosomal protein critical for cilia formation and function, essential in various tissues including the retina.

Patient and family guide: The CEP290 gene provides essential instructions for making a protein that acts like a gatekeeper in many cells of the body, particularly in the eye. In the retina, the light-sensing cells (photoreceptors) have a specialized structure called a cilium, which acts like a bridge connecting different parts of the cell. The CEP290 protein sits at this bridge and controls the traffic of important materials back and forth. This constant transport is absolutely necessary for the photoreceptors to detect light and send visual signals to the brain. When the CEP290 gene is mutated, the gatekeeper protein is either missing or doesn't work correctly. As a result, the vital traffic across the cellular bridge gets blocked. In the eye, this causes the light-sensing cells to slowly break down and die, leading to severe vision loss. Because the CEP290 protein is also used in cilia in other parts of the body, such as the kidneys and brain, some mutations can cause additional health problems in those organs, though many patients only experience vision loss. Conditions caused by CEP290 mutations are inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene—one from each parent—to develop the disease. The parents, who each carry one mutated copy and one normal copy, typically do not show any symptoms and are known as carriers. For families with a history of CEP290-related disease, genetic testing and counseling can help determine the risk of passing the condition to future children.

Gene function: CEP290 is vital for the proper formation and function of primary cilia in photoreceptor cells, which are essential for transporting molecules to the outer segments for phototransduction. Dysfunction of CEP290 leads to defective ciliary transport, impairing photoreceptor function and survival, resulting in severe inherited retinal degenerations like Leber congenital amaurosis.

Protein structure: The CEP290 gene encodes a large protein consisting of 2,479 amino acids with a molecular weight of approximately 290 kDa. The protein is highly structural, characterized by multiple coiled-coil domains that span much of its length. These coiled-coil regions are critical for protein-protein interactions, allowing CEP290 to act as a scaffold that binds to numerous other ciliary and centrosomal proteins. CEP290 contains an N-terminal domain that includes a highly conserved amphipathic helix motif, which facilitates direct binding to cellular membranes. It also possesses a myosin-tail homology domain essential for its localization and function. The protein localizes to the transition zone of primary cilia, where it assembles into a complex network, often forming Y-shaped linkers that connect the microtubule axoneme to the ciliary membrane. This structural arrangement is vital for its role as a gatekeeper regulating ciliary transport.

Molecular function: The CEP290 gene encodes a 290 kDa centrosomal and ciliary transition zone scaffold protein that is essential for the formation, maintenance, and function of primary cilia. In photoreceptor cells, the primary cilium is highly modified into the connecting cilium, which bridges the inner segment (where proteins are synthesized) and the outer segment (where phototransduction occurs). CEP290 localizes to the Y-links of the transition zone, acting as a critical gatekeeper that regulates the trafficking of proteins and lipids into and out of the ciliary compartment. At a molecular level, CEP290 interacts with numerous other ciliary proteins, including those mutated in other ciliopathies (e.g., NPHP5, CC2D2A, and various BBS proteins), forming complex protein networks essential for ciliary structural integrity. It plays a role in both early and late steps of ciliogenesis. In photoreceptors, CEP290 is required for the massive daily transport of opsins and other phototransduction cascade components to the outer segment. Loss of CEP290 function disrupts this transport, leading to the accumulation of proteins in the inner segment, failure of outer segment formation or maintenance, and ultimately, photoreceptor cell death.

Expression pattern: The CEP290 gene is ubiquitously expressed in ciliated cells throughout the body, reflecting its fundamental role in primary cilia function. In the eye, it is highly expressed in the photoreceptor cells of the retina, specifically localizing to the connecting cilium, a specialized transition zone between the inner and outer segments of rods and cones. This localization is critical for the transport of phototransduction proteins. Beyond the retina, CEP290 is expressed in the renal epithelium, where it is essential for the function of primary cilia in kidney tubules. It is also expressed in the brain, particularly in the cerebellum, and in the inner ear, olfactory epithelium, and respiratory tract. The broad expression pattern explains the pleiotropic nature of CEP290 mutations, which can affect multiple organ systems depending on the specific variant and its impact on protein function in different tissues.

Mutation spectrum: The mutation spectrum of CEP290 is highly diverse, with over 100 unique pathogenic variants identified to date. These include missense, nonsense, frameshift, splice-site mutations, and large deletions. The mutations are distributed throughout the gene's 54 exons, with no single major hotspot, though certain regions may be more prone to specific types of alterations. The most notable and frequent mutation is the deep intronic variant c.2991+1655A>G, which accounts for up to 20% of all LCA cases in Europe and North America. This mutation creates a cryptic splice donor site, leading to the inclusion of a pseudoexon and a premature stop codon. Founder mutations have also been identified in specific populations, such as a founder mutation in the French Canadian population associated with LCA. The wide variety of mutation types contributes to the broad clinical spectrum of CEP290-related disorders.

Pathogenic variants: 1. c.2991+1655A>G (p.Cys998X) - The most common pathogenic variant, a deep intronic mutation that causes aberrant splicing and is primarily associated with non-syndromic Leber congenital amaurosis (LCA10). 2. c.5668G>T (p.Gly1890*) - A nonsense mutation that leads to a premature stop codon, frequently associated with Joubert syndrome and more severe syndromic phenotypes. 3. c.4723A>T (p.Lys1575*) - Another nonsense mutation resulting in a truncated protein, reported in patients with Senior-Løken syndrome and LCA. 4. c.6401T>C (p.Leu2134Pro) - A missense mutation identified in compound heterozygosity in French Canadian patients with Joubert syndrome. 5. c.2268A>G (p.Ser756=) - A synonymous variant that affects splicing, reported as pathogenic for retinal dystrophy and LCA.

Clinical significance: Mutations in the CEP290 gene manifest clinically across a broad spectrum of conditions, ranging from isolated inherited retinal diseases (IRDs) to severe syndromic ciliopathies. The most common IRD associated with CEP290 is Leber congenital amaurosis (LCA), specifically LCA type 10, which accounts for 15-20% of all LCA cases. Patients typically present with profound visual loss from birth or early infancy, pendular nystagmus, photophobia, and an oculodigital sign (poking or rubbing the eyes). The fundus may initially appear normal or show peripheral white flecks, progressing to retinal pigmentation and RPE atrophy. In addition to non-syndromic LCA, CEP290 mutations can cause early-onset severe retinal dystrophy (EOSRD) and retinitis pigmentosa. Systemically, CEP290 mutations are a major cause of Joubert syndrome, characterized by neurological features such as hypotonia, ataxia, and the hallmark "molar tooth sign" on brain MRI, often accompanied by juvenile nephronophthisis. More severe syndromic manifestations include Senior-Løken syndrome (retinal dystrophy and renal disease), Bardet-Biedl syndrome, and the perinatal lethal Meckel-Gruber syndrome, which presents with renal cysts, occipital encephalocele, and polydactyly.

Inheritance: Autosomal Recessive

Chromosomal location: 12q21.32

Genotype-phenotype correlations: Establishing robust genotype-phenotype correlations for CEP290 has proven challenging due to the gene's pleiotropic nature and the wide clinical spectrum of associated diseases. However, some general patterns have emerged. Null mutations (e.g., nonsense, frameshift) that result in a complete loss of functional protein are typically associated with severe syndromic phenotypes like Meckel-Gruber syndrome or severe Joubert syndrome. Conversely, hypomorphic mutations that allow for some residual protein function are more often associated with non-syndromic retinal dystrophies like LCA or milder syndromic forms. The common deep intronic mutation c.2991+1655A>G is a classic example; it introduces a cryptic splice site leading to a premature stop codon in about 50-75% of transcripts, but the remaining wild-type transcripts produce enough functional protein to prevent severe systemic disease, restricting the phenotype primarily to the retina (LCA10). The presence of genetic modifiers is also thought to play a significant role in determining the final clinical presentation.

Research and therapeutic approaches: Therapeutic approaches for CEP290-associated retinal disease are currently a major focus of research, with several promising strategies in clinical trials. The most advanced approaches target the common deep intronic mutation c.2991+1655A>G. One notable strategy is CRISPR/Cas9-based in vivo gene editing. The therapy EDIT-101 is designed to remove or invert the pathogenic IVS26 variant, restoring normal splicing. Phase 1/2 clinical trials (e.g., BRILLIANCE) have shown that EDIT-101 can be safely administered via subretinal injection and has demonstrated efficacy in improving vision in some patients. Another significant approach involves antisense oligonucleotides (ASOs). Sepofarsen (QR-110) is an RNA-based therapy designed to bind to the mutated CEP290 pre-mRNA, blocking the cryptic splice site and restoring normal protein production. While early trials showed promise, recent Phase 2/3 trials had mixed results, highlighting the complexities of RNA therapeutics. Unlike RPE65-associated LCA, which has an FDA-approved gene augmentation therapy (Luxturna), the large size of the CEP290 gene (exceeding the packaging capacity of standard AAV vectors) makes traditional gene replacement challenging, driving the development of these alternative editing and RNA-modulation strategies.

Diagnostic testing: Mutations in the CEP290 gene are typically detected through next-generation sequencing (NGS) approaches. Targeted retinal gene panels are the most common initial diagnostic test, as they efficiently screen for known mutations across multiple IRD genes. If panel testing is inconclusive, whole exome sequencing (WES) or whole genome sequencing (WGS) may be employed. WGS is particularly valuable for identifying deep intronic variants, such as the common c.2991+1655A>G mutation, which might be missed by standard WES. Genetic counseling is a critical component of the diagnostic process. Since CEP290-related disorders follow an autosomal recessive inheritance pattern, parents of an affected individual are obligate carriers and have a 25% chance of having another affected child in subsequent pregnancies. Counselors must address the wide phenotypic variability of CEP290 mutations, explaining that even within the same family, the severity and systemic involvement can vary. Carrier screening is available for at-risk family members and prospective parents.

Animal models: Key animal models used to study CEP290 include the rd16 mouse and the rdAc cat. The rd16 mouse possesses an in-frame deletion of 897 base pairs in the Cep290 mRNA, resulting in a protein lacking 299 amino acids. This model exhibits rapid photoreceptor degeneration and is widely used to study disease mechanisms and test gene therapies. The rdAc cat is another naturally occurring model that helps delineate the role of CEP290 in regulating the formation and maintenance of cilia in photoreceptor cells. Zebrafish models carrying mutations in cep290 are also utilized. These models undergo progressive loss of cone photoreceptors and exhibit signs of microglia activation and inflammation. Zebrafish are particularly useful for studying the developmental aspects of ciliary function and for high-throughput screening of potential therapeutic compounds. Additionally, humanized mouse models, such as the HuCEP290 IVS26 KI mice, have been developed specifically to test gene-editing therapies like EDIT-101.

Population genetics: The carrier frequency for CEP290 mutations in the general population is estimated to be approximately 1 in 500 individuals, predicting a disease prevalence of about 1 in 1,000,000 for CEP290-related disorders overall. However, the prevalence varies significantly depending on the specific condition and population. For instance, CEP290 mutations are the most common cause of Leber congenital amaurosis (LCA), accounting for 15-20% of cases. The deep intronic mutation c.2991+1655A>G is particularly prevalent in populations of European and North American descent. Founder effects have also been observed, such as specific mutations enriched in the French Canadian population and certain regions of France, which can lead to higher local carrier frequencies and disease incidence.

Selected references: 1. den Hollander AI, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet. 2006. PMID: 16909394 2. Perrault I, et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat. 2007. PMID: 17345604 3. Coppieters F, et al. CEP290, a gene with many faces: mutation overview and update. Hum Mutat. 2010. PMID: 20690115 4. Sheck L, et al. Leber Congenital Amaurosis Associated with Mutations in CEP290, Clinical Phenotype, and Natural History in Preparation for Trials of Novel Therapies. Ophthalmology. 2018. PMID: 29398018 5. Pierce EA, et al. Gene Editing for CEP290-Associated Retinal Degeneration. N Engl J Med. 2024. PMID: 38712614 6. Valkenburg D, et al. Clinical Characterization of 66 Patients With Congenital Retinal Disease Due to the Deep-Intronic c.2991+1655A>G Mutation in CEP290. Invest Ophthalmol Vis Sci. 2018. PMID: 30193325 7. Valente EM, et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nat Genet. 2006. PMID: 16682970